Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06263491
Title Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.